HC Wainwright & Co. Reiterates Buy on Journey Medical, Maintains $13 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.9%

Neg 0% Neu 90.9% Pos 0%

HC Wainwright & Co. analyst Brandon Folkes reiterates Journey Medical (NASDAQ:DERM) with a Buy and maintains $13 price target.